Monday, 20 Nov 2017

You are here

Wearable Technologies Coming of Age

The first day of EULAR 2017 highlighted a symposium focus on the advances in wearable technologies. Several lectures updated attendees with the state of wearables in society and their implications on public health, fitness, weight loss and clinical trials.

These devices (Fitbit, Vivo fit, cellphones) make use of accelerometers that can be worn as a watch, or clip to thigh or hip. Many are worn on the thigh for the purpose of not only assessing movement but also positional change.  This is accomplished by measuring acceleration through different axes over time.  

The accelerometers have become smaller with improved sensitivity and updated software, making these devices ready for primetime use in life, practice and trials. 

Yet their use still requires a computer interface, and in the case of clinical trial use, may require patient entry into chronological diaries for data interpretation.

While these are cheap and easily implemented, some have questioned their accuracy by noting that different devices yield different results on the same patient.  Moreover, the most expensive devices are NOT necessarily the most accurate or “true”. For instance, the Mi Band (from China) is far cheaper than many currently sold “health trackers” in the USA.

Marie McCarthy from ICON reviewed the adoption of wearables in clinical research, noting that there is a growing interest in incorporating these into many current clinical trials.  She even prognosticated that within 2 years, wearable direct to patient (D2P) assessments would be in the majority of RCTs.

The advantage is that they allow for remote, between-visit monitoring, the acquisition of real life/real time data, and the measures are highly objective. The use of wearables in research may improve patient engagement, screening, recruitment or adherence (you can also send messages to the monitoring device). Their use creates new or novel endpoints and may allow for fewer patient visits – all the while maintaining proper monitoring.

Lastly, these devices are quite accurate in monitoring and reporting sleep – which is increasingly being reported as a surrogate or comorbid outcome in many diseases or with numerous treatments. 

The range of measures may extend beyond activity, sleep, temperature and heart rate and may, in the future, be capable of blood monitoring.  However, the ability to assess swollen joints, fatigue or biomarkers will have to remain on the wish-list, as the technology improves.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Podcast of ACR17 - Day 4

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr. Jack Cush reviews lupus and the microbiome, daily podcasts, pregnancy and lactation, osteoporosis drug holidays and screening for pulmonary hypertension.

Many thanks to the RheumNow Faculty for their work and expertise!

Podcast of ACR 17 - Day 3

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

ACR 2017 - Day 3 and 4 Highlights

Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report).  Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.